Abstract | Despite considerable advancements that shattered previously held dogmas about the metastatic cascade, the evolution of therapies to treat metastatic disease has not kept up. In this Opinion article, I argue that, rather than waiting for metastases to emerge before initiating treatment, it would be more effective to target metastatic seeds before they sprout. Specifically, I advocate directing therapies towards the niches that harbour dormant disseminated tumour cells to sensitize them to cytotoxic agents. Treatment sensitization, achieved by disrupting reservoirs of leukaemic stem cells and latent HIV, argues that this approach, although unconventional, could succeed in improving patient survival by delaying or even preventing metastasis.
, but 3 breakthroughs in the last 25 years have led to a widespread appreciation for the clinical phenomenon of latent disease, motivating a desire to target tumour cells while they 'sleep' . The ability to detect disseminated tumour cells (DTCs) 2 led to their discovery in patients with no evidence of metastatic disease [2] [3] [4] , indicating that tumour cells spread far earlier than previously thought (an idea substantiated in animal models 5, 6 ). Establishment of their prognostic significance 3, 4, [7] [8] [9] [10] [11] [12] [13] suggested that these DTCs could be the origin of future metastases. The continued detection of circulating tumour cells (CTCs) decades after successful treatment of the primary tumour [14] [15] [16] hinted that a fraction of DTCs survive therapy and remain dynamic based on their ability to consistently enter the circulation. This implied that dormant DTCs are actively regulated in a non-cell-intrinsic manner. Finally, the discovery that dormant DTCs persist at the single cell level 17, 18 , and that (similar to stem cells) their behaviour is regulated by a niche 19 , raises the possibility that we can target dormant DTCs by altering their microenvironment. This approach could result in a means of metastasis prevention.
The question is how to target dormant DTCs: do we reinforce their niche in an attempt to keep them asleep forever, or do we draw dormant DTCs out of their niche to kill them but potentially risk waking them up?
In this Opinion article, I argue that addressing this dilemma requires a detailed understanding of the cellular and biochemical composition of the microenvironment that harbours dormant DTCs -the 'dormant niche. ' I posit that distinct cues within this niche regulate engraftment, quiescence, survival and chemoresistance of dormant DTCs, raising the possibility that these cells can be sensitized to systemic therapy without necessarily affecting their growth status. Examples (primarily from haematopoietic cancers) show how this paradigm has been applied successfully to eradicate putative leukaemic stem cells from patients who were otherwise refractory to standard treatments, leading to substantially improved survival. Lessons from HIV research also suggest practical reasons why an approach to eradicate dormant DTCs is superior to chronic maintenance of the dormant state.
Tumour cell dormancy: a singular focus Biologically, tumour dormancy encompasses two distinct states: population-level dormancy and cellular dormancy 14, 20 . Population-level dormancy, first proposed by Judah Folkman in the early 1970s 21 , is a condition in which tumour-cell proliferation and death are balanced within micrometastatic foci owing to diffusion limitations and/or immune surveillance 22, 23 . In contrast, cellular dormancy describes a state of mitotic arrest in which cells have exited the cell cycle and entered the so-called G 0 state 14, 18, 20 . Although there is some debate as to which dormancy mechanism is more relevant, the reality is that these states are not mutually exclusive. Just as Folkman described the 'angiogenic switch' (REF. 24 ) as a barrier that must be overcome for tumour cell populations to progress to metastases 22, 24 , a 'dormancy switch' is probably a preliminary hurdle that must be overcome for quiescent DTCs to proliferate initially into micrometastases 19 . Therefore, both dormancy mechanisms and both switches require consideration when devising therapeutic strategies. Since the vast majority of DTCs in bone marrow and other tissues are found in a state that is consistent with cellular dormancy 17, 25 , and because anti-angiogenic strategies to maintain population-level dormancy have been discussed thoroughly elsewhere 26, 27 , the focus of this Perspective is cellular dormancy. It is important to note here that, although it is often assumed that late-arising metastases originate from dormant DTCs, current evidence is circumstantial. However, supportive data continue to accumulate; BOX 1 presents this evidence and discusses how the strategies presented in this article could result in direct proof of the clinical relevance of cellular dormancy.
Properties of dormant DTCs
Three essential properties define dormant DTCs: they persist within foreign microenvironments, they are reversibly growth-arrested and they resist targeted and cytotoxic treatments (FIG. 1a) . The ability of DTCs to persist in foreign tissues for many years in a growth-arrested state is well documented, and it is increasingly appreciated that the microenvironment has an important role in conferring and maintaining these states 28, 29 . However, the therapeutic resistance of dormant DTCs is a property that requires exploration.
Evidence that dormant DTCs resist common therapies is derived from their recovery from bone marrow aspirates of patients who underwent systemic treatment with chemotherapy regimens, such as those containing doxorubicin or targeted agents like trastuzumab, several years earlier 7, [30] [31] [32] . Subsequent imaging-based studies in mice clearly showed that single DTCs persist beyond doxorubicin treatment 33 . Why these cells resist therapy has been historically based on two assumptions.
One assumption is that tumour progression is linear; according to this theory, DTCs arise from cells that left the primary tumour in the later stages of the disease, are further evolved than the primary tumour and have accumulated mutations that confer resistance to the applied drug(s). However, comparative genomic hybridization studies comparing DTCs isolated from bone marrow with matched primary breast tumour cells showed that DTCs have fewer genomic aberrations on a per-cell basis than tumour cells from the primary site. These studies further showed that the majority of DTCs lack any detectable chromosomal abnormalities 34 . These findings have also been substantiated in patients with prostate cancer using DTCs taken as long as 8 years following radical prostatectomy 35 . Both studies support the notion that DTCs depart early in primary tumour development, and suggest that it is unlikely that early DTCs inherently resist therapy.
A second assumption is that cytotoxic therapies, which target rapidly dividing cells, do not detrimentally affect dormant DTCs because they are not cycling. However, mitotic state is not the only factor that determines susceptibility to apoptosis-inducing agents 36 . In particular, the identification of discrete pathways that regulate growth and polarity of mammary epithelium in three-dimensional culture showed that niche-mediated cellular architecture protects tumour cells from cytotoxic therapy. In these cultures, malignant cells form disorganized, continuously growing clusters that respond to both cytotoxic agents and tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) agonists, whereas tumour cells driven into growth-arrested and properly polarized three-dimensional structures by phenotypic reversion were resistant to each of the death-inducing agents applied 37 . The key result is that forcing growth of organized colonies did not lead to enhanced chemotherapeutic efficacy as long as these colonies maintained their cellular architecture. Instead, disrupting the polarity of quiescent colonies (without inducing growth) dramatically increased cytotoxicity 37 . One crucial insight gained from this work is that chemoresistant cells can be made to be susceptible to cytotoxic agents without affecting their growth status. Another insight is that the basement membrane is a principle effector of signalling that promotes drug resistance. This is supported by experiments conducted with multiple tumour types and different classes of cytotoxic agents [38] [39] [40] [41] . Taking these data into account, we can pinpoint a niche that harbours DTCs, confers each of the essential properties listed above, and could be targeted for the purpose of treating dormant DTCs.
Defining the dormant niche
In addition to conferring drug resistance, the basement membrane promotes survival and induces the functional differentiation and growth arrest of epithelial cells. Merely disrupting adhesion of a single integrin subunit to laminin 111, a principle basement membrane component, causes mammary epithelial cell apoptosis 42 , showing that specific tethers to basement membrane are crucial survival cues. Similarly, key features of the normal phenotype, such as growth arrest and functional differentiation, are achieved only when mammary epithelial cells are adhered to the basement membrane (principally laminin 111) or are within a microenvironment that facilitates its endogenous production [43] [44] [45] [46] [47] . Thus, the basement membrane confers each of the properties associated with DTC dormancy when epithelial cells or epithelialderived tumour cells are adhered to 'native' basement membrane. However, following dissemination, DTCs no longer interact with the epithelial basement membrane from their tissue of origin. Instead, DTCs often take a haematogenous route to foreign tissues, such as lung, bone marrow, liver or brain 48 , where vascular basement membrane is the first basement membrane they encounter. Therefore, it is not surprising that dormant DTCs are found in close association with vascular basement membrane, a phenomenon observed in both spontaneous and experimental mouse models of breast tumour dissemination 19 and through live imaging studies tracking disseminated melanoma and lung cancer cells in the brains of mice 49 . Indeed, over the past 15 years, evidence has accumulated that the niche surrounding the microvasculature -the perivascular niche (PVN) -orchestrates a number of processes related to tissue growth, differentiation and regeneration 50 . Key roles for the endothelium have been established in the regulation of pancreatic differentiation 51 ; liver growth 52 and regeneration 53, 54 ; glomerulogenesis and nephrogenesis in the kidney 55, 56 ; lung regeneration 57 ; bone remodelling 58, 59 ; and neuronal development and differentiation 60 . Most relevant to this discussion is the part played by the PVN in conferring the essential properties of DTCs (principally survival and growth arrest) to tissue-resident stem cells -a population of cells maintained in number until triggered to repopulate tissue, much like dormant DTCs.
Box 1 | Do dormant disseminated tumour cells initiate metastases?
Currently, it is not possible to directly prove that dormant disseminated tumour cells (DTCs) initiate metastases. We are not able to follow a single DTC for years to determine whether it ever awakens and colonizes tissue, nor are we able to eliminate DTCs in any organism to determine whether progression is altered. However, there are a number of indirect lines of evidence that are supportive of a metastasis-initiating role of dormant DTCs. The first is that, in contrast to circulating epithelial cells (some inflammatory syndromes cause epithelial cells to circulate in the blood [146] [147] [148] ), disseminated epithelial cells have not been found in healthy individuals. However, when they are discovered in the bone marrow of patients with breast, lung, prostate, colorectal, gastric or oesophageal cancer, their presence correlates with significantly reduced metastasis-free survival 4, [7] [8] [9] 11, 12, 149 . The second is that isolated DTCs have expansion potential and can cause metastases once reinoculated into the host organism. DTCs have been isolated and expanded successfully in cultures from mouse models and clinical specimens (although immortalization was required for the latter) 150, 151 . Further, DTCs isolated from the bone marrow of immunocompromised mice formed primary tumours once re-implanted into the mammary fat pad, and went on to colonize the lymph nodes and lung tissue 151 . However, reinoculated cells remained dormant in bone marrow. Therefore, isolated and expanded DTCs cause metastatic disease, but may not gain the ability to colonize new sites without permissive changes in the microenvironment that trigger micrometastatic outgrowth 19, [121] [122] [123] [124] [125] [152] [153] [154] . As mentioned at the outset, all of these correlations are circumstantial. The ultimate proof has to come from establishing a causal relationship between DTC elimination and extension of metastasis-free survival. Ironically, this will never happen without a treatment that successfully addresses dormant DTCs. • CXCL12
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• Laminins The stem cell niche and the dormant niche: one and the same? The idea of a specialized microenvironment that regulates stem cell behaviour is one that was first proposed formally by Schofield 61 , who postulated that a niche restricts stem cell differentiation and cell-cycle entry in order to maintain the stem cell population of a tissue. The vascular endothelium has become known as a prominent component of the stem cell niche 50, 62 (FIG. 1b-d ). Tissue-specific stem cells in brain, bone marrow, skeletal muscle and skin tissues localize to haematogenous vasculature [63] [64] [65] [66] , and mesenchymal stem cells within muscle and pancreatic tissues also reside on microvasculature 67 . Endothelial-cell-derived factors are key effectors of stem cell phenotype in each of these tissues 50 .
Whereas stem cells and dormant DTCs both occupy PVNs, there is currently no direct evidence that these niches are identical. However, there are three pieces of evidence to suggest that this association is more than coincidental. The first is that careful analysis of efferent blood in rat models of mammary carcinoma established that primary tumour size correlates with the number of cells shed into circulation 68 ; however, no such relationship between primary tumour size and the number of DTCs detected in bone marrow exists, as shown in humans with cancer 5, 7, 69 . This implies that CTCs can engraft only a limited number of niches in bone marrow 69 , consistent with the idea that stem cell niches in bone marrow are limited in size and number 70, 71 . Second, recent evidence supporting one of Schofield's original assertions -that stem cell niches can impose features of a stem cell on (nonstem) daughter cells 62, 72, 73 -suggests that these specialized microenvironments could indeed support survival and regulate the growth of DTCs as well (FIG. 2 illustrates this parallel). The last, and perhaps strongest, piece of evidence in support of this hypothesis is that the same cues used to mobilize haematopoietic stem cells (HSCs) from bone marrow also result in the mobilization of DTCs. Application of granulocyte colonystimulating factor (G-CSF, also known as CSF3), or inhibition of the CXC-chemokine ligand 12 (CXCL12)-CXC-chemokine receptor 4 (CXCR4) signalling axis, results in mobilization of HSCs from bone marrow into the bloodstream 74 . In 1994, growing concern over the strategies used to collect transforming growth factorβ2 (TGFβ2) and growth arrestspecific 6 (GAS6) mediate DTC quiescence in bone marrow. Factors known to drive and maintain haematopoietic stem cell (HSC) quiescence (for example, CXCL4, stem cell factor (SCF) and angiopoietin 1 (ANG1)) may also act on DTCs in the bone marrow. Additionally, osteopontin may drive the chemo resistance of solid tumour cells, as it does for leukaemic cells. Finally, in the brain, osteopontin, laminins (primarily lamininα2) and Notch ligands are niche constituents of stemlike glioblastoma cells, whereas ephrin B2 is a known inducer of neural stem cell quiescence. These factors may also act on DTCs in the brain, which require initial adhesion to the perivasculature to survive. Osteopontin and nitric oxide drive therapeutic resistance of glioblastoma cells, and these perivascular cues may also function to confer resistance to dormant DTCs. CAR, CXCL12abundant reticular; ECM, extracellular matrix; NSC, neural stem cell. Nature Reviews | Cancer HSCs for reintroduction into patients after high-dose chemotherapy led to the discovery that blood taken from G-CSF-treated patients with multiple myeloma was contaminated with tumour cells 75 . This result has since been leveraged for patients with solid tumours to increase CTC numbers for diagnostic purposes 76 . Recently, it was shown that inhibition of CXCR4 in mice releases disseminated prostate cancer cells from the bone marrow into circulation, showing that HSCs and prostate cancer cells are tethered to niches in bone marrow by the same signal 77 . Whether dormant DTCs are also tethered to bone marrow niches by CXCR4, and whether stem cell niches and dormant niches overlap in other tissues, remains to be seen. Dormant DTCs: a product of their microenvironment. Dormant DTCs may or may not occupy de facto stem cell niches on vasculature. In either case, it is clear that perivascular tumour cells exhibit each of the properties shared by stem cells and dormant DTCs (FIG. 1a) . The use of intravital imaging to track individual DTCs within mouse brains showed that adhesion to the basal side of microvasculature is an absolute prerequisite for DTC survival 49 , and studies in zebrafish and chicken embryos indicate that connexin-mediated signalling between the endothelium and DTCs mediates this effect 78 . Growth-arrested DTCs also persist on, or very close to, lung and bone marrow microvasculature, and recreating the microvascular niche of these tissues with human cells showed that stable micro vascular endothelium induces and sustains breast tumour cell quiescence 19 . Endothelialderived thrombospondin 1 (TSP1; also known as THBS1), which associates with mature microvascular basement membrane, is a prime effector of this phenotype 19 . Given the complexity of the basement membrane and the matricellular proteins that associate with it 79 , several additional factors within the PVN probably have direct and indirect roles in sustaining DTC quiescence. To this end, additional constituents of the dormant niche have been identified. An emerging theme is that these molecules signal in a tissue-specific manner (FIG. 1b-d) .
Using experimental metastasis assays in syngeneic mice, the bone morphogenetic protein (BMP) antagonist COCO (also known as DAND5) was pinpointed as a factor that enables dormant DTCs to colonize lung tissue 80 . This finding implies that BMPs have a key role in restricting DTC growth in lung tissue, with BMP4 the most likely effector of dormancy 80 . Although an angiocrine source of BMP4 was not tested, it is worth noting that, in this study, dormant cells resided exclusively on lung micro vasculature; more recent work has shown that autocrine BMP4 signalling by lung endothelium results in TSP1 expression, which drives alveolar differentiation of lung stem cells 81 . Notably, the dormancy-associated functions of BMP4 may not translate to other tissues, such as bone marrow or brain tissue 80, 82 . 82, 83 . The intertwining of PVN and endosteum 84 raises the possibility that osteoblast-derived effectors of quiescence (for example, growth arrest-specific 6 (GAS6) 85 ) may also act on perivascular DTCs.
What role any of these factors have in mediating chemoresistance of dormant DTCs beyond inducing growth arrest is unknown; currently, there is no evidence that perivascular cues specifically mediate therapeutic resistance of dormant DTCs. However, support for this concept continues to accumulate in the setting of both primary tumours and distant metastases. For instance, glioblastoma cells residing on brain microvasculature acquire stem celllike properties 86 ; this phenotype is mediated by perivascular nitric oxide, Notch signalling and CD44-mediated and integrin α 6 -mediated binding to PVN components (for example, osteopontin and laminin α2) [87] [88] [89] [90] [91] (FIG. 1d) . Perivascular glioblastoma cells resist radiotherapy 92 and upregulate expression of the drug transporter ABC transporter G family member 2 (ABCG2) 87 , which prevents intracellular accumulation of chemotherapeutics such as methotrexate, mitoxantrone and anthracyclins 93 . Additionally, the PVN provides a therapeutic safe haven in the metastatic context. Colorectal cancer cells expressing the putative cancer stem cell marker CD133 are found to be concentrated on the microvasculature of liver metastases in human specimens. Media conditioned by liver endothelial cells enrich for CD133-positive tumour cells that are highly resistant to the chemotherapeutics 5-fluorouracil and oxaliplatin. An endothelial-cell-derived, proteolytically shed form of the Notch ligand jagged 1 is the principal effector of this phenotype 94 . Liver endothelium is also implicated in lymphoma cell survival; angiocrine jagged 1 is the culprit here as well, driving doxorubicin resistance and manifesting in a more aggressive form of the disease in mice 95 . Finally, chemotherapeutic treatments also directly alter the angiocrine profile of endothelium; in response to taxol, doxorubicin and cyclophosphamide, lung endothelial cells trigger a signalling cascade through the release of TNF that directly and indirectly sustains DTC survival 96 .
The message is not only that the PVN elicits each of the properties associated with dormant DTCs, but also that this occurs through mechanisms that are specific to the vascular bed of each tissue 97 (FIG. 1b-d ). This reflects a functional diversity among the cells, basement membrane molecules and soluble effectors that comprise the PVN of each organ. Therefore, an understanding of tissue-specific perivascular heterogeneity between tissues is necessary to determine whether there are universal properties of the PVN that can be exploited to sustain tumour dormancy or eradicate dormant tumour cells, or whether a more tailored approach that takes specific organ PVNs into account (and perhaps even their sub-niches; see BOX 2) is required.
Targeting dormant DTCs
Clinical and experimental evidence supports the therapeutic potential of targeting dormant DTCs to prevent metastasis
and a role for the PVN in conferring crucial properties of dormant DTCs. The question now is how to leverage this knowledge to treat dormant DTCs: should we try to keep them asleep by supplementation of key niche factors or, instead, should we kill them by disrupting interactions with supportive microenvironmental cues? The HIV field is similarly plagued by the issue of minimal residual disease and provides a striking and potentially instructive parallel to this dilemma.
Antiretroviral therapy (ART) is an extremely effective treatment regimen that drives viraemia (the concentration of virus in plasma) down to undetectable levels in individuals infected with HIV 98 . However, ART does not eradicate the virus altogether. HIV persists in a latent but replicationcompetent form in a small subset of extremely long-lived resting memory CD4 + T cells [99] [100] [101] . Perpetual application of ART to keep HIV in a dormant state is now in its second decade; however, concerns with its longterm toxicity, cost and re-emergence of HIV once ART is halted prevent it from being an ideal permanent solution 102 . Perhaps this is a cautionary tale for strategies aimed at keeping dormant DTCs at bay indefinitely.
Instead, researchers have pursued an alternative strategy aimed at disrupting HIV latency in CD4 + T cells so that ART can target the replicative virus successfully. In this context, the recent discovery that protein kinase C activators and histone deacetylase inhibitors significantly upregulate HIV transcript expression in resting CD4 + T cells derived from people with HIV who had undergone ART 103,104 is promising. However, a lingering concern is whether eradicating HIV from resting memory CD4 + T cells will result in the total depletion of HIV throughout the body 102 . Researchers may effectively eliminate residual virus within the CD4 + T cell population only to find that there are other reservoirs of latent HIV. This provides a point of caution for approaches aimed at targeting dormant DTCs as well: even a strategy that is successful in one tissue must be tested extensively to determine whether it eliminates dormant DTCs in other tissues. Below, these two strategies are explored in the context of dormant DTCs. 46, [106] [107] [108] [109] . SRC family kinases are another potential target 110 , and transcript profiling of single or small pools of DTCs promises to reveal more potential targets [111] [112] [113] [114] . An alternative to the chronic suppression of pathways that are typically activated in malignant cells is to instead induce expression of dormancy-initiating or dormancymaintenance factors in DTCs (FIG. 3) . For instance, the stress-activated protein kinase p38 and homeobox transcription factor D10 (HOXD10) are known drivers of dormancy in different cancers 115, 116 . Therefore, strategies aimed at inducing and/or sustaining p38 or HOXD10 signalling in dormant DTCs could theoretically result in maintenance of tumour dormancy.
Other than directly altering DTC physiology, a different tactic is to deliver constituents of the dormant niche in an attempt to permanently maintain DTC growth arrest. Ostensibly, this niche-based approach would cause minimal side effects as it involves supplementation of naturally occurring factors. However, delivery of TSP1 and other extracellular matrix (ECM)-derived glycoproteins that could mediate DTC quiescence presents a substantial hurdle because of their size 117 . One strategy to overcome this hurdle is to induce expression of these molecules instead (FIG. 3b) . A five-amino acid peptide has been identified, derived from the TSP1-inducing Box 2 | The niche within the niche: sub-niche heterogeneity A theme of this Opinion article is that one cannot assume the existence of a one-size fits all approach to targeting dormant disseminated tumour cells (DTCs), because tissue-specific differences could underlie how DTCs resist chemotherapy in different organs (FIG. 1) . However, an emerging paradigm in both the stem cell and dormancy literature is that sub-niches within tissues exhibit heterogeneity in terms of how their molecular repertoire drives cells into or out of quiescence. For instance, painstaking analysis of tissue-specific knockouts identified the haematopoietic stem cell (HSC) niche in bone marrow as perivascular in nature 74, 155 , but recent work has elaborated two additional perivascular locales (periarteriolar niches and megakaryocytic niches) that maintain populations of dormant HSCs through distinct molecular mechanisms 156, 157 . Even two cells on the same microvessel can experience different signalling environments; endothelial stalks are surrounded by mature basement membrane, which steers cells towards a quiescent state, whereas endothelial tip cells deposit a host of mitogenic factors that drive growth 19 . This signalling paradigm is also found in epithelial tubes of the embryonic mouse lung 158 . The bottom line: location matters, and determining exactly how much could be the difference between developing a therapy that works against only some DTCs or against them all. Nature Reviews | Cancer Mobilization glycoprotein prosaposin 117, 118 , that stimulates TSP1 expression systemically. In mice bearing tumours from orthotopic injection of breast cancer cells, those treated with the peptide had a significantly reduced lung metastatic burden compared with scrambled peptide treated controls 117 , demonstrating the promise of a prophylactic, niche-based approach to prevent outgrowth of dormant DTCs.
What are the drawbacks of keeping DTCs dormant? Toxicity associated with sustained induction of key signalling proteins like p38 or sustained expression of dormant niche factors like TSP1 would need to be defined rigorously. For example, TSP1 has potent anti-angiogenic activity in addition to its antitumour functions 119 . How would its chronic systemic induction affect physiologic processes? Another consideration is that the dormant niche can be subverted -by definition, dormant DTCs can eventually 'wake up. ' Although supplementing niche-derived factors may prevent this from happening through natural degradation of key niche factors (for example, ageing), this strategy may fail against strong and sustained induction (for example, by wounding or inflammation) that could overwhelm the dormant niche 19, 120 . Accordingly, a parallel line of investigation is to identify metastatic niche components -extracellular factors that promote DTC outgrowth 121 . These components include ECM proteins (such as fibronectin 122 , periostin 123 , versican 124 and tenascin-C
125
) that are expressed abundantly during development, but subside in the adult organism. Ectopic re-expression by activated stroma 122, 123, 125 or endothelial tip cells 19 drives metastatic outgrowth. Thus, in theory, sustained inhibition of critical receptors for metastatic niche components (for example, integrin α v β 3 ) could be a viable strategy -perhaps in combination with induction of dormancyinitiating factors -to prevent activation of the dormant switch.
Although promising, practical issues (such as clinical trial enrolment and expense, patient adherence and, ultimately, patient expenditure) have to be factored into the cost-benefit analysis of any dormancy maintenance strategy. Convincing patients who already have a good prognosis that they should take a drug indefinitely poses a challenge, and funding a clinical trial based on the endpoint of extension of metastasis-free survival -many years down the road for this patient population -could prove troublesome given that clinical trial costs increase with time. Additionally, treatment adherence and reporting are expected management burdens that become increasingly problematic with time owing to difficulty tracking patients and maintaining standards for dosing frequency. Indeed, persistence of patient adherence to a prescribed regimen for management of a chronic condition drops off strikingly after the first 6 months, which is a challenge not faced by more acute treatments 126 . This could pose a serious hurdle to arriving at a clinically meaningful, statistically significant conclusion about the efficacy of a dormancy-maintenance regimen 127 . Last, even if successful, whether the patient is willing and able to pay for a given treatment is an additional consideration. For instance, despite the findings of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, which showed significant reduction in recurrence and mortality when survivors of breast cancer continued tamoxifen treatment for 10 years versus the usual 5-year period 128 , some health care providers have reportedly balked at paying the costs of tamoxifen for the additional 5 years. Knowing that the expense of a dormancy maintaining drug is probably, at some point, going to be passed onto the patient could limit the market, and thus interest, of drug companies willing to explore this treatment avenue. Taking all of these practical concerns into account, one could argue that developing a strategy to kill dormant DTCs is the preferable option.
Option 2: killing dormant DTCs. A therapy that eradicates dormant DTCs would not suffer from the same practical concerns as chronic dormancy-maintenance therapy. Patient enrolment in trials would be simpler because treatment would be employed acutely around the time of surgery, when systemic neoadjuvant or adjuvant therapies are already administered (FIG. 3a) . Both strategies would ultimately rely on a long-term indicator (metastasis-free survival) for proof of efficacy; however, when killing dormant DTCs, the elimination of DTCs from bone marrow aspirates within a year of treatment offers a near-term indicator of therapeutic efficacy. Such a near-term indicator does not exist for chronic dormancy-maintenance. Notably, a smaller-scale trial has already established a basis for using DTC presence as a surrogate for long-term survival 129 . Importantly, data on the ability of highly promising candidate drugs to sensitize DTCs to therapy could be gathered initially even in patients with metastatic disease, provided that their bone marrow is DTC-positive but free of metastases. Thus, enrolment criteria for trials of DTC-killing therapies would be less stringent than for dormancy maintenance therapies, which would be limited to patients with early-stage cancer by necessity.
How could we selectively induce the death of dormant DTCs? A strategy based on targeting the 'survival niche' is one idea that has been broached elsewhere 29 . Alternatively, because evidence presented in the prior section implicates the PVN in endowing DTCs with therapeutic resistance, a combinatorial approach that prefaces chemotherapeutic delivery with targeted disruption of key tethers to mobilize DTCs from the PVN (FIG. 3c) is another exciting possibility. Successful salvage regimens used for haematopoietic cancers provide a blueprint for this approach.
Most patients with acute myeloid leukaemia (AML) eventually become refractory to standard cytotoxic therapy. Treatmentresistant leukaemic stem cells (LSCs) persist and ultimately reconstitute the disease. Their adhesion to chemoprotective niches is thought to play a major part in this 130 . LSCs are found in both osteoblastic niches and PVNs in bone marrow 95, [131] [132] [133] [134] . Factors derived from these niches, namely CXCL12 and osteopontin, have major roles in mediating adhesion, temporary cell cycle arrest and chemoresistance of LSCs 135, 136 . Accordingly, an alternative therapeutic strategy was formulated for patients with AML who were refractory to standard treatments, which involved evicting LSCs from their therapeutic safe havens before cytotoxic therapy administration. G-CSF was the first mobilizing agent used, and it quickly gained traction as the FLAG (a combination of fludarabine and ara-C with G-CSF priming) salvage regimen 137, 138 . More recently, G-CSF priming in combination with other cytotoxic agents has resulted in a complete remission rate of 46% in populations of patients with refractory AML 139 . Current approaches employ a more niche-targeted approach, using antagonists to receptors for the niche constituents CXCL12 (that is, CXCR4 antagonists) and osteopontin (that is, CD44 and integrin α 4 β 1 antagonists) to mobilize resistant leukaemic cells. In fact, the use of CXCR4 inhibitors to sensitize refractory AML cells to chemotherapy has already entered clinical trials 140 , and inhibition of osteopontin has proved effective in reducing minimal residual disease burden in preclinical models 135 . These results show the viability and promise of strategies aimed at displacing tumour cells from a protective niche in order to eradicate them altogether.
A principle consideration is how to apply such a strategy to DTCs of solid tumour origin. Owing to its crucial role in directing and retaining both HSCs and tumour cells to bone marrow 77, 141, 142 , the CXCL12-CXCR4 axis clearly overlaps among some tumour types. Provocative data indicate that bone marrow-engrafted DTCs are mobilized into the blood by application of G-CSF 76 and by inhibition of CXCL12-CXCR4 signalling 77 , providing proof-of-principle that DTCs can be mobilized from their niche. It remains to be seen whether these approaches sensitize mobilized DTCs to chemotherapy without exacerbating HSC mobilization and/or depletion (which would present a major complication); however, this is one promising avenue of exploration.
The spectre that looms over this debate is whether mobilizing DTCs from the dormant niche will result in their awakening, an unpalatable and potentially undesirable side effect. Here, two points should be considered. The first is that this result would not necessarily be disastrous. Employment of mathematical models analogous to those pioneered by Norton and Simon 143 for the treatment of invasive breast cancer could define reliable windows in which to deploy cytotoxic therapy and kill vulnerable DTCs before they undergo multiple cell divisions. Such a model would have to account for DTC mobilization rates and cell-cycle dynamics, which would necessitate careful measurement.
The second is the distinct possibility that DTC chemosensitization will not require growth induction. Data demonstrating that tissue architecture is more crucial than growth state in determining therapeutic resistance of breast tumour cells 37 has been discussed already. Additional evidence suggests that it is also possible to mobilize DTCs without triggering their growth. For example, proliferation of dormant HSCs can be stimulated directly by interferon-α, without displacing HSCs from their niche, or indirectly by G-CSF, which cleaves a number of niche tethers, resulting in mobilization of HSCs from the stem cell niche and proliferation 144 . However, interfering with a growthsuppressive microenvironment does not necessarily mean that a cell will proliferate, as often assumed. Here, the role of osteopontin in leukaemic cell engraftment is illustrative. Dormant leukaemia cells co localize with osteopontin in the osteo blastic niche. Targeting osteopontin receptors or osteopontin itself results in sensitization of dormant leukaemic cells to the cytotoxin ara-C 135 . Interestingly, unlike G-CSF 145 , osteopontin inhibition does not directly alter cell-cycle progression of leukaemia cells 135 , suggesting that it has a chemoprotective role within a dormancy-inducing microenvironment, where other factors induce quiescence.
The implication is that distinct molecules within the dormant niche convey each of the dormancy-related properties described in FIG. 1 . Thus, the identification of dormant niche constituents that independently regulate DTC proliferation and chemosensitivity is urgently needed to formulate viable strategies to chemosensitize dormant DTCs without eliciting their growth (FIG. 3c) . Successful implementation of such an approach could result in substantially reduced risk of metastatic relapse in patients with early disseminated disease.
Concluding perspectives
The above argues that those researching solid tumours should take a cue from colleagues researching HIV and haematopoietic cancers and invest more effort in identifying therapies that target the dormant niche. Our goal should be to sensitize the 'sleeping giants' that these niches protect from current therapies. As the dormant niche is perivascular and the PVN provides crucial survival and therapeutic resistance cues to dormant DTCs, strategies to mobilize DTCs from this microenvironment are necessary.
Which PVNs do we target? Because most of our clinical understanding about the behaviour of dormant DTCs derives from bone marrow aspirates, which sample only ~0.4% of one potential metastatic site, we have little idea of what the typical DTC burden of a patient with early-stage cancer is. Therefore, it is important to understand how far dormant DTCs have spread. It is also important to determine whether the mechanisms that govern resistance of dormant DTCs are tissue-specific, or whether unifying principles exist that will enable us to target dormant DTCs universally. This will require a comprehensive molecular description of the PVN in each tissue, which will have to be crosschecked against a catalogue of functionally relevant stem cell niche anchors so that collateral damage to stem cell populations is prevented.
The final hurdle will be to determine which patients receive dormant nichetargeted agents before therapeutic administration. The immediate inclination would be to administer this regimen to all early-stage patients with DTC-positive bone marrow aspirates. However, we do not know who within this patient population will progress. Approximately two-thirds of patients with breast cancer and DTC-positive bone marrow have a good prognosis 7 -is this because their DTCs have a functional shortcoming that prevents them from proliferating in a foreign tissue, or is it because their DTCs never see microenvironmental triggers that awaken them? The answer will determine whether the combinatorial strategy proposed is unnecessary for some or appropriate for all. 
